These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27391309)

  • 21. Neoadjuvant cisplatin for head and neck cancer: Simulation of a novel schedule for improved therapeutic ratio.
    Marcu LG; Bezak E
    J Theor Biol; 2012 Mar; 297():41-7. PubMed ID: 22182756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer.
    Newlin HE; Amdur RJ; Riggs CE; Morris CG; Kirwan JM; Mendenhall WM
    Cancer; 2010 Oct; 116(19):4533-40. PubMed ID: 20572028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
    Kuhnt T; Mueller AC; Pelz T; Haensgen G; Bloching M; Koesling S; Schubert J; Dunst J
    J Cancer Res Clin Oncol; 2005 Nov; 131(11):758-64. PubMed ID: 16088405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma.
    Morse RT; Ganju RG; TenNapel MJ; Neupane P; Kakarala K; Shnayder Y; Chen AM; Lominska CE
    Head Neck; 2019 Aug; 41(8):2492-2499. PubMed ID: 30856297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
    Rades D; Seidl D; Janssen S; Bajrovic A; Hakim SG; Wollenberg B; Schild SE
    Oral Oncol; 2016 Jun; 57():40-5. PubMed ID: 27208843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoradiotherapy with high-dose cisplatin compared with weekly cisplatin for locally advanced head and neck squamous cell carcinoma.
    Hughes RT; Porosnicu M; Levine BJ; Lycan TW; Shenker RF; Frizzell BA; Greven KM
    J Med Imaging Radiat Oncol; 2021 Oct; 65(6):796-805. PubMed ID: 34309212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of low adherence to weekly cisplatin with outcomes in patients with head and neck squamous cell carcinoma: a retrospective cohort study.
    Virk J; Gill J; Fekrmandi F; Iovoli A; Farrugia M; Al-Afif A; Wooten K; Gupta V; McSpadden R; Kuriakose MA; Markiewicz MR; Hicks WL; Ma SJ; Singh AK
    BMC Cancer; 2024 Jul; 24(1):838. PubMed ID: 39003442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Forastiere AA; Metch B; Schuller DE; Ensley JF; Hutchins LF; Triozzi P; Kish JA; McClure S; VonFeldt E; Williamson SK
    J Clin Oncol; 1992 Aug; 10(8):1245-51. PubMed ID: 1634913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer.
    Melotek JM; Cooper BT; Koshy M; Silverman JS; Spiotto MT
    J Otolaryngol Head Neck Surg; 2016 Nov; 45(1):62. PubMed ID: 27881143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerated Fractionation Plus Chemotherapy
    Rades D; Narvaez CA; Janssen S; SchrÖder U; Bruchhage KL; Hakim SG; Bartscht T; Schild SE
    Anticancer Res; 2021 Feb; 41(2):877-884. PubMed ID: 33517293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.
    Perez CA; Wu X; Amsbaugh MJ; Gosain R; Claudino WM; Yusuf M; Roberts T; Jain D; Jenson A; Khanal S; Silverman CI; Tennant P; Bumpous JM; Dunlap NE; Rai SN; Redman RA
    Oral Oncol; 2017 Apr; 67():24-28. PubMed ID: 28351577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of VEGF and FLT-1 receptor expression in patients with locally advanced squamous cell carcinoma of the head and neck.
    Seibold ND; Schild SE; Bruchhage KL; Gebhard MP; Noack F; Rades D
    Strahlenther Onkol; 2013 Aug; 189(8):639-46. PubMed ID: 23748230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
    Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
    Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
    Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck: Japan Clinical Oncology Group Study (JCOG1008).
    Kunieda F; Kiyota N; Tahara M; Kodaira T; Hayashi R; Ishikura S; Mizusawa J; Nakamura K; Fukuda H; Fujii M;
    Jpn J Clin Oncol; 2014 Aug; 44(8):770-4. PubMed ID: 24842866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC).
    Guan J; Zhang Y; Li Q; Zhang Y; Li L; Chen M; Xiao N; Chen L
    Oncotarget; 2016 Oct; 7(43):70185-70193. PubMed ID: 27602493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK.
    Ho KF; Swindell R; Brammer CV
    Acta Oncol; 2008; 47(8):1513-8. PubMed ID: 18607863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Su NW; Leu YS; Lee JC; Chen YJ; Chen HW; Liu CJ; Chang YF
    Acta Otolaryngol; 2011 Dec; 131(12):1333-40. PubMed ID: 22017375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.